[18F]FDG and [18F]FLT PET for the Evaluation of Response to Neo-adjuvant Chemotherapy in a Model of Triple Negative Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 May 24

PMID 29791503

Citations 12

Authors

Isabella Raccagni

Sara Belloli

Silvia Valtorta

Alessandro Stefano

Luca Presotto

Claudio Pascali

Anna Bogni

Monica Tortoreto

Nadia Zaffaroni

Maria Grazia Daidone

Giorgio Russo

Emilio Bombardieri

Rosa Maria Moresco

Affiliations

Soon will be listed here.

Abstract

Rationale: Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response).

Methods: Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F]FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm.

Results: We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmax similarly defined tumor response to therapy and that SUVmax variation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline.

Conclusions: Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel.

Citing Articles

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.

Castorina L, Comis A, Prestifilippo A, Quartuccio N, Panareo S, Filippi L J Clin Med. 2024; 13(1).

PMID: 38202160 PMC: 10779934. DOI: 10.3390/jcm13010154.

Evaluating [F]FDG and [F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models.

Rainone P, Valtorta S, Villa C, Todde S, Cadamuro M, Bertoli G Int J Mol Sci. 2023; 24(18).

PMID: 37762429 PMC: 10532149. DOI: 10.3390/ijms241814124.

Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).

Sunassee E, Jardim-Perassi B, Madonna M, Ordway B, Ramanujam N Mol Cancer Res. 2023; 21(10):995-1009.

PMID: 37343066 PMC: 10592445. DOI: 10.1158/1541-7786.MCR-22-1004.

Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.

Mankoff D, Pantel A, Viswanath V, Karp J Curr Pathobiol Rep. 2023; 7(3):97-108.

PMID: 37092138 PMC: 10117535. DOI: 10.1007/s40139-019-00202-9.

A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative Cu-Labeled Chelator in Mouse Models.

Benfante V, Stefano A, Comelli A, Giaccone P, Cammarata F, Richiusa S J Imaging. 2022; 8(4).

PMID: 35448219 PMC: 9025273. DOI: 10.3390/jimaging8040092.

References

Amendt C, Staub E, Friese-Hamim M, Storkel S, Stroh C . Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer. Clin Cancer Res. 2014; 20(17):4478-87. DOI: 10.1158/1078-0432.CCR-13-3385. View

Groheux D, Hindie E, Marty M, Espie M, Rubello D, Vercellino L . ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Eur J Radiol. 2014; 83(10):1925-33. DOI: 10.1016/j.ejrad.2014.05.037. View

Pascali C, Bogni A, Fugazza L, Cucchi C, Crispu O, Laera L . Simple preparation and purification of ethanol-free solutions of 3'-deoxy-3'-[18F]fluorothymidine by means of disposable solid-phase extraction cartridges. Nucl Med Biol. 2011; 39(4):540-50. DOI: 10.1016/j.nucmedbio.2011.10.005. View

Bensch F, van Kruchten M, Lamberts L, Schroder C, Hospers G, Brouwers A . Molecular imaging for monitoring treatment response in breast cancer patients. Eur J Pharmacol. 2013; 717(1-3):2-11. DOI: 10.1016/j.ejphar.2013.01.079. View

Jensen M, Erichsen K, Bjorkling F, Madsen J, Jensen P, Sehested M . Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET. PLoS One. 2014; 8(12):e85126. PMC: 3873431. DOI: 10.1371/journal.pone.0085126. View

Lopergolo A, Perrone R, Tortoreto M, Doria F, Beretta G, Zuco V . Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer. Oncotarget. 2016; 7(31):49649-49663. PMC: 5226536. DOI: 10.18632/oncotarget.10105. View

Malhotra G, Zhao X, Band H, Band V . Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010; 10(10):955-60. PMC: 3047091. DOI: 10.4161/cbt.10.10.13879. View

Le Du F, Eckhardt B, Lim B, Litton J, Moulder S, Meric-Bernstam F . Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 2015; 6(15):12890-908. PMC: 4536987. DOI: 10.18632/oncotarget.3849. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

10.

Humbert O, Riedinger J, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V . Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2015; 21(24):5460-8. DOI: 10.1158/1078-0432.CCR-15-0384. View

11.

Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G . 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget. 2015; 6(30):29388-95. PMC: 4745734. DOI: 10.18632/oncotarget.5001. View

12.

Honndorf V, Schmidt H, Wiehr S, Wehrl H, Quintanilla-Martinez L, Stahlschmidt A . The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model. Mol Imaging Biol. 2015; 18(2):249-57. DOI: 10.1007/s11307-015-0881-1. View

13.

Woolf D, Beresford M, Li S, Dowsett M, Sanghera B, Wong W . Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer. 2014; 110(12):2847-54. PMC: 4056049. DOI: 10.1038/bjc.2014.207. View

14.

Mollard S, Mousseau Y, Baaj Y, Richard L, Cook-Moreau J, Monteil J . How can grafted breast cancer models be optimized?. Cancer Biol Ther. 2011; 12(10):855-64. PMC: 3280900. DOI: 10.4161/cbt.12.10.18139. View

15.

Pio B, Park C, Pietras R, Hsueh W, Satyamurthy N, Pegram M . Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2005; 8(1):36-42. DOI: 10.1007/s11307-005-0029-9. View

16.

Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M . Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015; 8:177-93. PMC: 4303459. DOI: 10.2147/OTT.S67673. View

17.

Hatt M, Groheux D, Martineau A, Espie M, Hindie E, Giacchetti S . Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med. 2013; 54(3):341-9. DOI: 10.2967/jnumed.112.108837. View

18.

Groheux D, Giacchetti S, Espie M, Rubello D, Moretti J, Hindie E . Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2010; 38(3):419-25. DOI: 10.1007/s00259-010-1660-5. View

19.

Kenny L, Coombes R, Vigushin D, Al-Nahhas A, Shousha S, Aboagye E . Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007; 34(9):1339-47. DOI: 10.1007/s00259-007-0379-4. View

20.

Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A . ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging. 2015; 42(6):818-30. DOI: 10.1007/s00259-015-2995-8. View